TY - JOUR
T1 - Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-alpha in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3
AU - Nelson, David R.
AU - Benhamou, Yves
AU - Chuang, Wan-Long
AU - Lawitz, Eric J.
AU - Rodriguez-Torres, Maribel
AU - Flisiak, Robert
AU - Rasenack, Jens W. F.
AU - Kryczka, Wieslaw
AU - Lee, Chuan-mo
AU - Bain, Vincent G.
AU - Pianko, Stephen
AU - Patel, Keyur
AU - Cronin, Patrick W.
AU - Pulkstenis, Erik
AU - Subramanian, G. Mani
AU - Mchutchison, John G.
AU - Team, AS
PY - 2010
Y1 - 2010
N2 - BACKGROUND & AIMS: A phase 3 active-controlled study was conducted to assess the efficacy/safety of albinterferon alfa-2b (albIFN), a novel, long-acting, genetic fusion polypeptide of recombinant human albumin and interferon alfa-2b, in patients with chronic hepatitis C virus (HCV) genotype 2/3. METHODS: In all, 933 patients were randomized to open-label subcutaneous treatment with pegylated interferon-alfa-2a (Peg-IFNalfa-2a) 180 mu g/wk, or albIFN 900 or 1200 mu g every 2 weeks for 24 weeks, each administered with oral ribavirin 800 mg/day. The primary end point of the study was sustained virologic response (SVR) (HCV-RNA level, < 15 IU/mL at week 48). During the study, the data monitoring committee recommended dose modification for all patients receiving albIFN 1200 mu g to 900 mu g, impacting 38% of this treatment arm. RESULTS: By intention-to-treat analysis, SVR rates were 84.8% (95% confidence interval, 80.4%-88.6%), 79.8% (95% confidence interval, 74.9%-84.1%), and 80.0% (95% confidence interval, 75.1%-84.3%) with Peg-IFNalfa-2a, and albIFN 900 and 1200 mu g, respectively. The primary hypothesis of noninferiority of SVR was established for albIFN 900 mu g (P = .009) and 1200 mu g (P = .006). Independent positive predictors of SVR by multivariate regression analysis were pretreatment HCV-RNA level less than 400,000 IU/mL, age younger than 45 years, body mass index less than 30 kg/m(2), genotype 2, normal gamma-glutamyl transpeptidase and increased alanine aminotransferase levels at baseline, fibrosis stage F0-F2, no steatosis, and Asian geographic region (Peg-IFNalfa-2a only). The 3 treatment groups showed similar rates of serious (7%-8%) and severe (13%-16%) adverse events, and discontinuations owing to adverse events (3.6%-5.5%). CONCLUSION: Albinterferon alfa-2b 900 mu g every 2 weeks provides an alternative efficacious treatment option in patients with chronic HCV genotype 2 or 3.
AB - BACKGROUND & AIMS: A phase 3 active-controlled study was conducted to assess the efficacy/safety of albinterferon alfa-2b (albIFN), a novel, long-acting, genetic fusion polypeptide of recombinant human albumin and interferon alfa-2b, in patients with chronic hepatitis C virus (HCV) genotype 2/3. METHODS: In all, 933 patients were randomized to open-label subcutaneous treatment with pegylated interferon-alfa-2a (Peg-IFNalfa-2a) 180 mu g/wk, or albIFN 900 or 1200 mu g every 2 weeks for 24 weeks, each administered with oral ribavirin 800 mg/day. The primary end point of the study was sustained virologic response (SVR) (HCV-RNA level, < 15 IU/mL at week 48). During the study, the data monitoring committee recommended dose modification for all patients receiving albIFN 1200 mu g to 900 mu g, impacting 38% of this treatment arm. RESULTS: By intention-to-treat analysis, SVR rates were 84.8% (95% confidence interval, 80.4%-88.6%), 79.8% (95% confidence interval, 74.9%-84.1%), and 80.0% (95% confidence interval, 75.1%-84.3%) with Peg-IFNalfa-2a, and albIFN 900 and 1200 mu g, respectively. The primary hypothesis of noninferiority of SVR was established for albIFN 900 mu g (P = .009) and 1200 mu g (P = .006). Independent positive predictors of SVR by multivariate regression analysis were pretreatment HCV-RNA level less than 400,000 IU/mL, age younger than 45 years, body mass index less than 30 kg/m(2), genotype 2, normal gamma-glutamyl transpeptidase and increased alanine aminotransferase levels at baseline, fibrosis stage F0-F2, no steatosis, and Asian geographic region (Peg-IFNalfa-2a only). The 3 treatment groups showed similar rates of serious (7%-8%) and severe (13%-16%) adverse events, and discontinuations owing to adverse events (3.6%-5.5%). CONCLUSION: Albinterferon alfa-2b 900 mu g every 2 weeks provides an alternative efficacious treatment option in patients with chronic HCV genotype 2 or 3.
KW - ACHIEVE
KW - CLEARANCE
KW - COMBINATION
KW - FUSION PROTEIN
KW - GENETIC-VARIATION
KW - HCV GENOTYPE-2
KW - IL28B
KW - INFECTION
KW - PEGINTERFERON ALPHA-2B
KW - PLUS RIBAVIRIN
KW - Pegylated Interferon-Alfa
KW - Sustained Virologic Response
KW - THERAPY
KW - albIFN
U2 - 10.1053/j.gastro.2010.06.062
DO - 10.1053/j.gastro.2010.06.062
M3 - Journal Article
SN - 0016-5085
VL - 139
SP - 1267
JO - Gastroenterology
JF - Gastroenterology
IS - 4
ER -
